סיכונים

AXTI · China export permits remain unreliable or materially delayed

PKE · Valuation multiple compression (demanding vs current earnings/FCF)

PKE · Customer/program concentration (GE/MRAS + Aerojet ~51% of FY2026; top five ~72%)

GRAL · FDA approval delayed, denied, narrowed, or burdened

GRAL · Reimbursement fails to expand beyond limited/self-pay channels

GRAL · Mortality benefit unproven; payer skepticism after NHS-Galleri primary endpoint miss

GRAL · Volume growth without high-quality reimbursed adoption (self-pay/discounted)

GRAL · ASP compression from channel mix and consumer pricing

GRAL · High cash burn may require further dilutive financing

GRAL · Competition from Guardant Shield MCD and Exact/Abbott Cancerguard

NTRA · Valuation already prices in years of successful execution

NTRA · Signatera oncology growth slows materially

NTRA · Signatera realized ASP and payer-specific rates not disclosed; economics may be weaker than implied

NTRA · MRD competitors achieve stronger evidence or payer traction

NTRA · Operating expenses grow faster than revenue; operating leverage fails

NTRA · Payer policies/guidelines turn technology-neutral and price-sensitive

AXTI · Valuation prices in growth before revenue, margin and cash-flow proof

AXTI · InP demand fails to convert into AXTI revenue and economics

AXTI · Sumitomo, Coherent or Chinese producers expand competitive supply

AXTI · Reported backlog is cancellable, double-ordered or shortage-inflated

AXTI · Dilution or capital allocation weakens per-share returns

AXTI · Tongmei / noncontrolling-interest economics reduce value to AXTI common holders

PKE · Margins deteriorate structurally or C2(R)B mix worsens

PKE · Raw-material/ArianeGroup bottlenecks and missed shipments

PKE · New-plant cost escalation, underutilization, or ATM dilution

PKE · Larger competitors or loss of qualification/certification/sole-source status

NTRA · GAAP profitability remains distant; positive cash flow is management-defined